Clinical Trial Update: TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

The TREND-02 trial update describes a Phase II exploratory neoadjuvant study of sacituzumab govitecan plus tislelizumab in early triple-negative breast cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: First Hospital of China Medical University | Conditions: TNBC, Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING